Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Decline in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 5,752 shares, a decrease of 99.4% from the October 15th total of 919,936 shares. Currently, 4.5% of the company’s stock are sold short. Based on an average daily trading volume, of 48,213 shares, the short-interest ratio is presently 0.1 days.

Biodexa Pharmaceuticals Stock Performance

NASDAQ:BDRX opened at $2.46 on Wednesday. The business has a fifty day moving average price of $4.79 and a 200-day moving average price of $23.04. Biodexa Pharmaceuticals has a one year low of $2.28 and a one year high of $357.60.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a specialty pharmaceutical company focused on developing and commercializing therapies for rare and difficult-to-treat diseases, with an emphasis on oncology and neurological conditions. The company’s programs are designed to address areas where existing treatment options are limited. Biodexa has developed drug-delivery technologies intended to improve the administration, targeting and duration of pharmaceutical treatments. Its portfolio has included Q-Sphera, a platform for producing long-acting injectable medicines, as well as development programs involving therapies delivered directly to tumors or the central nervous system.